Followers | 837 |
Posts | 120317 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Monday, May 24, 2010 1:30:05 AM
IDIX ReadMeFirst
[Updates:
text of Thomas Weisel report with $9 price target;
link to HCV article in C&EN (thanks, turtlepower);
new version of “The New Battle Lines in HIV”;
new version of “HCV: Most Likely to Succeed.”]
What is IDIX’s business all about?
IDIX’s drug portfolio
#msg-49736882 Transcript of 1Q10 conference call
#msg-50505854 Thomas Weisel report with $9 target (4/23/10)
HCV primer from IDIX website
Valuation and finances
#msg-49729060 1Q10 financial results
#msg-49729792 Liquidity and cash usage
#msg-50505854 Thomas Weisel report with $9 target (4/23/10)
#msg-49743057 Milestone payments from GSK
#msg-35740500 Tyzeka royalty stream worth ~$25M
#msg-49569765 Latest financing transaction
#msg-49785732 Share count for valuation purposes
News flow
#msg-49733218 2010-2011 news flow
Officers, directors, and major shareholders
#msg-49743604 Composition of Board of Directors
#msg-48436375 Tamar Howson fills open seat on BoD
Capsule résumés of executive officers (click on a name)
#msg-37998991 NVS, IDIX revise terms of relationship
#msg-49997072 Largest shareholders include NVS and GSK
#msg-49785817 Chronology of NVS’ equity stake
#msg-46731440 Current insider shareholdings
#msg-44704472 Recent insider transactions
HCV program: Economic rationale and competition
#msg-50504707 HCV: Most Likely to Succeed (IMHO)
#msg-50505854 Thomas Weisel report with $9 target (4/23/10)
#msg-38956178 HCV market forecast from Decision Resources
#msg-40127105 Up-front payments of HCV partnerships
#msg-29018192 Prevalence and incidence of HCV in the US
#msg-30190435 Devastating risk of undertreating HCV
#msg-34694166 US prevalence of genotypes 1a and 1b
#msg-34797714 Annual sales of ifn-alpha drugs
#msg-36780163 Musings on combining agents from different classes
#msg-48546028 Musings on combination therapy vis-à-vis NVS
#msg-34925415 Interferon and the Law of Diminishing Returns
HCV program: IDX184 nucleotide polymerase inhibitor
#msg-49003061 Interim phase-2a data look very nice! (table)
#msg-49096739 Interim phase-2a data look very nice (PR)
#msg-49731578 All-oral cocktail of IDX184+IDX320 (1)
#msg-49732533 All-oral cocktail of IDX184+IDX320 (2)
#msg-49115388 Why nucleotides are better than nucleosides
#msg-39719159 Phase-1b monotherapy data
#msg-49055353 Replicon data in combination with other IDIX drugs (1)
#msg-47954632 Replicon data in combination with other IDIX drugs (2)
#msg-43046863 NVS declines to license IDX184
#msg-43102142 Musings on NVS’ decision (dewophile)
#msg-49116246 Possible IDX184 interest by Roche (1)
#msg-49123150 Possible IDX184 interest by Roche (2)
#msg-26915921 How IDX184 is unlike NM283
HCV program: IDX320 protease inhibitor
#msg-45598790 Rationale for IDX320 program
#msg-49731578 All-oral cocktail of IDX184+IDX320 (1)
#msg-49732533 All-oral cocktail of IDX184+IDX320 (2)
#msg-49055353 Phase-1 PK and drug-interaction data
#msg-47954632 Replicon data in combination with other IDIX drugs
#msg-36600884 Musings on selectivity of HCV PI’s
HCV program: IDX375 non-nucleoside polymerase inhibitor
#msg-45350536 Initial data from phase-1 SAD study
#msg-49055353 Replicon data in combination with other IDIX drugs (1)
#msg-47954632 Replicon data in combination with other IDIX drugs (2)
#msg-37246670 EASL 2009 press release
#msg-34334563 Blurb on IDX375 from hivandhepatitis.com
HIV program
#msg-50277627 The New Battle Lines in HIV
#msg-35391933 IDIX, GSK ink IDX899 collaboration
#msg-43254006 GSK/PFE launch ViiV Healthcare
#msg-49507158 IDIX receives $6.5M milestone from GSK (4/23/10)
#msg-49743057 Remaining IDX899 milestone payments from GSK
#msg-49687153 Sustiva (which IDX899 might supersede) sells $1.3B/yr
#msg-47558107 Design of IDX899 phase-2b trials
#msg-48915175 How GSK is planning for a “nuke-sparing” trial
#msg-49282477 Why GSK is planning for a “nuke-sparing” trial
#msg-37495719 Anticipated duration of a phase-2b trial
#msg-44790049 PK/food trial
#msg-31925486 Phase-1/2 IDX899 monotherapy data (PR)
#msg-31944395 Phase-1/2 IDX899 monotherapy data (chart)
#msg-46084532 IDX899 paper in Curr Opin Investigational Drugs
#msg-45984817 HIV market data from GILD’s 4Q09 CC
#msg-35674369 HIV market overview (2007 article from CNNMoney)
#msg-34894135 Musings on Truvada’s patent status
#msg-31175781 HIV incidence in US is higher than previously thought
#msg-31419107 Increased HIV screening will expand market
#msg-33124429 New guidelines to recommend earlier treatment (1)
#msg-36745396 New guidelines to recommend earlier treatment (2)
#msg-37210627 Half of untreated US carriers are in 350-500 CD4 range
#msg-29985830 Design of a late-stage HIV trial
Reference links
#msg-49716235 Overview of the HCV arena (from C&EN)
http://www.idenix.com/hepc/about
HCV drugs on market and in development
HIV drugs on market and in development
http://www.hivandhepatitis.com
[Updates:
text of Thomas Weisel report with $9 price target;
link to HCV article in C&EN (thanks, turtlepower);
new version of “The New Battle Lines in HIV”;
new version of “HCV: Most Likely to Succeed.”]
What is IDIX’s business all about?
IDIX’s drug portfolio
#msg-49736882 Transcript of 1Q10 conference call
#msg-50505854 Thomas Weisel report with $9 target (4/23/10)
HCV primer from IDIX website
Valuation and finances
#msg-49729060 1Q10 financial results
#msg-49729792 Liquidity and cash usage
#msg-50505854 Thomas Weisel report with $9 target (4/23/10)
#msg-49743057 Milestone payments from GSK
#msg-35740500 Tyzeka royalty stream worth ~$25M
#msg-49569765 Latest financing transaction
#msg-49785732 Share count for valuation purposes
News flow
#msg-49733218 2010-2011 news flow
Officers, directors, and major shareholders
#msg-49743604 Composition of Board of Directors
#msg-48436375 Tamar Howson fills open seat on BoD
Capsule résumés of executive officers (click on a name)
#msg-37998991 NVS, IDIX revise terms of relationship
#msg-49997072 Largest shareholders include NVS and GSK
#msg-49785817 Chronology of NVS’ equity stake
#msg-46731440 Current insider shareholdings
#msg-44704472 Recent insider transactions
HCV program: Economic rationale and competition
#msg-50504707 HCV: Most Likely to Succeed (IMHO)
#msg-50505854 Thomas Weisel report with $9 target (4/23/10)
#msg-38956178 HCV market forecast from Decision Resources
#msg-40127105 Up-front payments of HCV partnerships
#msg-29018192 Prevalence and incidence of HCV in the US
#msg-30190435 Devastating risk of undertreating HCV
#msg-34694166 US prevalence of genotypes 1a and 1b
#msg-34797714 Annual sales of ifn-alpha drugs
#msg-36780163 Musings on combining agents from different classes
#msg-48546028 Musings on combination therapy vis-à-vis NVS
#msg-34925415 Interferon and the Law of Diminishing Returns
HCV program: IDX184 nucleotide polymerase inhibitor
#msg-49003061 Interim phase-2a data look very nice! (table)
#msg-49096739 Interim phase-2a data look very nice (PR)
#msg-49731578 All-oral cocktail of IDX184+IDX320 (1)
#msg-49732533 All-oral cocktail of IDX184+IDX320 (2)
#msg-49115388 Why nucleotides are better than nucleosides
#msg-39719159 Phase-1b monotherapy data
#msg-49055353 Replicon data in combination with other IDIX drugs (1)
#msg-47954632 Replicon data in combination with other IDIX drugs (2)
#msg-43046863 NVS declines to license IDX184
#msg-43102142 Musings on NVS’ decision (dewophile)
#msg-49116246 Possible IDX184 interest by Roche (1)
#msg-49123150 Possible IDX184 interest by Roche (2)
#msg-26915921 How IDX184 is unlike NM283
HCV program: IDX320 protease inhibitor
#msg-45598790 Rationale for IDX320 program
#msg-49731578 All-oral cocktail of IDX184+IDX320 (1)
#msg-49732533 All-oral cocktail of IDX184+IDX320 (2)
#msg-49055353 Phase-1 PK and drug-interaction data
#msg-47954632 Replicon data in combination with other IDIX drugs
#msg-36600884 Musings on selectivity of HCV PI’s
HCV program: IDX375 non-nucleoside polymerase inhibitor
#msg-45350536 Initial data from phase-1 SAD study
#msg-49055353 Replicon data in combination with other IDIX drugs (1)
#msg-47954632 Replicon data in combination with other IDIX drugs (2)
#msg-37246670 EASL 2009 press release
#msg-34334563 Blurb on IDX375 from hivandhepatitis.com
HIV program
#msg-50277627 The New Battle Lines in HIV
#msg-35391933 IDIX, GSK ink IDX899 collaboration
#msg-43254006 GSK/PFE launch ViiV Healthcare
#msg-49507158 IDIX receives $6.5M milestone from GSK (4/23/10)
#msg-49743057 Remaining IDX899 milestone payments from GSK
#msg-49687153 Sustiva (which IDX899 might supersede) sells $1.3B/yr
#msg-47558107 Design of IDX899 phase-2b trials
#msg-48915175 How GSK is planning for a “nuke-sparing” trial
#msg-49282477 Why GSK is planning for a “nuke-sparing” trial
#msg-37495719 Anticipated duration of a phase-2b trial
#msg-44790049 PK/food trial
#msg-31925486 Phase-1/2 IDX899 monotherapy data (PR)
#msg-31944395 Phase-1/2 IDX899 monotherapy data (chart)
#msg-46084532 IDX899 paper in Curr Opin Investigational Drugs
#msg-45984817 HIV market data from GILD’s 4Q09 CC
#msg-35674369 HIV market overview (2007 article from CNNMoney)
#msg-34894135 Musings on Truvada’s patent status
#msg-31175781 HIV incidence in US is higher than previously thought
#msg-31419107 Increased HIV screening will expand market
#msg-33124429 New guidelines to recommend earlier treatment (1)
#msg-36745396 New guidelines to recommend earlier treatment (2)
#msg-37210627 Half of untreated US carriers are in 350-500 CD4 range
#msg-29985830 Design of a late-stage HIV trial
Reference links
#msg-49716235 Overview of the HCV arena (from C&EN)
http://www.idenix.com/hepc/about
HCV drugs on market and in development
HIV drugs on market and in development
http://www.hivandhepatitis.com
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.